In a report released today, Akash Tewari from Jefferies reiterated a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report), with a price target of $110.00. The company’s shares opened today at $54.42.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Tewari covers the Healthcare sector, focusing on stocks such as Pfizer, Regeneron, and BioNTech SE. According to TipRanks, Tewari has an average return of 4.7% and a 41.22% success rate on recommended stocks.
BioMarin Pharmaceutical has an analyst consensus of Moderate Buy, with a price target consensus of $94.27, representing a 73.23% upside. In a report released on June 19, Bernstein also maintained a Buy rating on the stock with a $95.00 price target.
The company has a one-year high of $94.85 and a one-year low of $52.93. Currently, BioMarin Pharmaceutical has an average volume of 2.1M.
Read More on BMRN:
- BioMarin reports new data underscoring the long-term efficacy of ROCTAVIAN
- BioMarin Pharmaceutical: Hold Rating Maintained Amid Competitive Pressures and New Data Insights
- BioMarin Pharmaceutical: Navigating Competitive Challenges with Strategic Growth Potential
- BioMarin Pharmaceutical’s Promising Pipeline and Strategic Focus Justify Buy Rating
- BioMarin Pharmaceutical Approves Equity Plan Amendment